End Gas Station Heroin Act
Sponsored By: Representative Gooden, Lance [R-TX-5]
Introduced
Summary
Adds 7-hydroxymitragynine and mitragynine pseudoindoxyl to Schedule I and creates a focused federal enforcement path for very potent synthetic opioids while carving narrow exemptions for natural kratom in finished products that meet strict limits.
Show full summary
- People who use drugs and families: Federal action may not be based solely on simple possession. Enforcement targets knowing or intentional manufacture, distribution, import, export, or possession with intent to distribute.
- Kratom consumers and sellers: Naturally occurring 7-OH or mitragynine pseudoindoxyl in finished kratom products can be exempt if concentrations stay at or below 1 mg per gram for solids or 1 mg per milliliter for liquids, and do not exceed 1 part per 100 parts mitragynine by mass. Substances that are synthesized, concentrated, isolated, or otherwise manufactured lose that exemption.
- Researchers, manufacturers, and regulators: The bill sets seven strict criteria for a "covered emerging synthetic opioid," including greater potency than morphine and an intent for human consumption. If a substance meets those criteria, it can be treated as Schedule I for commercial manufacture and distribution, while legitimate research, medical, and law enforcement uses are excluded.
Personalized for You
How does this bill affect your finances?
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
2 provisions identified: 0 benefits, 0 costs, 2 mixed.
Tighter limits on kratom products
If enacted, the bill would add two kratom-derived compounds to Schedule I: 7‑hydroxymitragynine and mitragynine pseudoindoxyl. Natural kratom products would be exempt only if each compound is ≤1 mg per gram for solids and ≤1 mg per milliliter for liquids. The combined amount must be ≤1 part per 100 parts mitragynine by mass. Any compound made, concentrated, isolated, or chemically converted by manufacturing would not get the exemption. Commercial makers and sellers of non-exempt products would be subject to federal Schedule I enforcement.
New rules for synthetic opioids
If enacted, the bill would create a new legal category, “covered emerging synthetic opioids,” that must meet seven strict tests before federal commercial enforcement applies. To qualify a substance must be chemically made or semisynthesized, intended for human consumption, shown by reliable evidence to be more potent than morphine at opioid receptors or in effects, not FDA approved, being or intended for commercial distribution, not already scheduled, and not excluded. The bill would limit federal enforcement to knowing or intentional commercial acts like manufacture, import, export, distribution, dispensing, or possession with intent. It would bar enforcement based only on purchase, receipt, simple possession, or personal use, and would protect samples held for legitimate research or testing. The Attorney General would be able to choose whether to proceed under this section, the Analogue Enforcement Act, or other federal law when both apply.
Sponsors & CoSponsors
Sponsor
Gooden, Lance [R-TX-5]
TX • R
Cosponsors
Rep. McCormick, Richard [R-GA-7]
GA • R
Sponsored 9/4/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov